β受体阻滞剂联合曲美他嗪对冠心病患者运动耐量的影响研究

发布时间：2018-06-28 15:52

本文选题：β受体阻滞剂 + 曲美他嗪　；参考：《重庆医学》2017年11期

【摘要】：目的探讨β受体阻滞剂联合曲美他嗪对冠心病患者运动耐量的影响。方法选取2014年1月至2015年9月该院收治的120例冠心病患者作为研究对象,分为观察组与对照组,每组60例。对照组采用β受体阻滞剂进行治疗,观察组在此基础上加用曲美他嗪进行治疗。比较两组的治疗效果及运动耐量指标变化。结果治疗后3个月,观察组治疗有效率为91.7%,对照组为73.3%,两组差异有统计学意义(χ~2=6.98,P0.01)。治疗前,两组各项运动耐量的指标相比,差异无统计学意义(P0.05);治疗后3个月,两组达到运动终点时间、最大心率、运动试验阳性例数及6 min最大步行距离相比差异有统计学意义(t/χ~2=9.81、8.78、8.34和9.21,P0.05)。结论β受体阻滞剂联合曲美他嗪治疗能够提高疗效,同时有效改善患者的运动耐量,值得临床推广使用。
[Abstract]:Objective to investigate the effect of 尾-receptor blocker combined with trimetazidine on exercise tolerance in patients with coronary heart disease. Methods 120 patients with coronary heart disease from January 2014 to September 2015 were divided into observation group and control group with 60 cases in each group. The control group was treated with 尾-blocker, and the observation group was treated with trimetazidine. The therapeutic effect and the changes of exercise tolerance were compared between the two groups. Results three months after treatment, the effective rate of treatment was 91.7 in the observation group and 73.3 in the control group. The difference between the two groups was statistically significant (蠂 2, 6.98, P0.01). Before treatment, there was no significant difference in the indexes of exercise tolerance between the two groups (P0.05). 3 months after treatment, the two groups reached the end time of exercise and the maximum heart rate. There were significant differences in the number of positive cases in exercise test and the maximum walking distance of 6 min (t / 蠂 ~ (2 +) ~ (9.81) ~ (8.78) and (9.21) (P0.05). Conclusion 尾-receptor blocker combined with trimetazidine can improve the efficacy and exercise tolerance of patients.
【作者单位】：贵州省遵义市红花岗区人民医院心内科;
【分类号】：R541.4

【相似文献】